PHARMACOKINETICS OF LIPOSOME-ENCAPSULATED ANTI-TUMOR DRUGS - STUDIES WITH VINBLASTINE, ACTINOMYCIN-D, CYTOSINE-ARABINOSIDE, AND DAUNOMYCIN
PHARMACOKINETICS OF LIPOSOME-ENCAPSULATED ANTI-TUMOR DRUGS - STUDIES WITH VINBLASTINE, ACTINOMYCIN-D, CYTOSINE-ARABINOSIDE, AND DAUNOMYCIN
复制标题
DOI:
10.1016/0006-2952(78)90252-6
复制
发表时间:
1978-01-01
影响因子:
5.8
通讯作者:
STAMP, D
中科院分区:
文献类型:
--
作者:
JULIANO, RL;STAMP, D
The effects of encapsulation within liposomes (phospholipid vesicles) on the plasma clearance kinetics and tissue disposition of 4 antitumor drugs, vinblastine, cytosine arabinoside, actinomycin-D and daunomycin were investigated in rats. In each case, subsequent to i.v. administration the liposome-encapsulated drugs were cleared from the plasma more slowly than the free drugs. The major portion of daunomycin injected in free form had a plasma half-life of less than 5 min, while liposome-encapsulated daunomycin had a plasma half-life in excess of 150 min. Encapsulation also caused a marked alteration in the tissue disposition of the injected drugs. Encapsulation within liposomes resulted in a large increase in the total amount of drug equivalents retained by the tissues at various times after injection. In the case of cytosine arabinoside, the level of drug equivalents in the liver at 16 h postinjection was 68-fold greater for liposome-encapsulated drug than free drug. Encapsulation also altered the relative distribution of drugs in the tissues, with tissues rich in reticuloendothelial cells, such as liver and spleen, being the favored sites of uptake.